Daniel M. Skovronsky, M.D., Ph.D.
President Lilly Research Laboratories Chief Scientific & Medical Officer, Eli Lilly and Company
Dan Skovronsky is the chief scientific and medical officer of Eli Lilly and Company and president of Lilly Research Laboratories. He also has responsibility for global business development.
Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics, vice president diabetes research, and most recently, senior vice president, clinical and product development. Dan has been closely involved in progress across all of Lilly’s therapeutic areas, including leading the recent acquisitions of Loxo Oncology and Prevail Therapeutics, the development of Lilly’s anti-COVID monoclonal antibodies, and Lilly’s progress in Alzheimer’s disease.
Dan is a neuroscientist and neuropathologist, having completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.
Follow Dan on LinkedIn to see his latest updates.
